New can­cer tar­get? GSK high­lights on­col­o­gy am­bi­tions with its move in­to the clin­ic with RIP1 drug for pan­cre­at­ic can­cer

Re­searchers for Glax­o­SmithK­line are launch­ing a clin­i­cal pro­gram for a RIP1 ki­nase drug in pan­cre­at­ic can­cer af­ter nail­ing down a pos­i­tive look at how this …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER